AR105975A1 - Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer - Google Patents
Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncerInfo
- Publication number
- AR105975A1 AR105975A1 ARP160102755A ARP160102755A AR105975A1 AR 105975 A1 AR105975 A1 AR 105975A1 AR P160102755 A ARP160102755 A AR P160102755A AR P160102755 A ARP160102755 A AR P160102755A AR 105975 A1 AR105975 A1 AR 105975A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- aryl
- nr1r2
- haloalkoxy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- -1 cyano, nitro, amino Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 102000009561 Forkhead Box Protein O1 Human genes 0.000 abstract 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000004995 haloalkylthio group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un género de derivados de arilsulfonamida de compuestos tricíclicos limitados heterocíclicos. Los compuestos inducen la translocación del factor de transcripción FOXO1 al núcleo mediante la modulación de PP2A y, como consecuencia, presentan efectos antiproliferativos. Son útiles en el tratamiento de diversos trastornos, incluso como una terapia en el tratamiento oncológico, o se utilizan en combinación con otros fármacos para restaurar la sensibilidad a la quimioterapia donde se ha desarrollado resistencia. Reivindicación 1: Un compuesto de fórmula (1), donde D se selecciona de un enlace directo, -O-, -CH₂O, -OCH₂-,-C(=O)NRD- y -N(RD)C(=O)-; RD se selecciona de hidrógeno y alquilo C₁₋₆; T es un anillo de benceno o un anillo heteroaromático de cinco o seis miembros; U es un anillo de benceno o un anillo heteroaromático de cinco o seis miembros; X¹, X², X³ y X⁴ se seleccionan independientemente, en cada instancia, de hidrógeno, halógeno, nitro, ciano, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, haloalquiltio C₁₋₆, -NR¹R², -OR¹, -C(O)R¹, -OC(O)R¹, -C(O)NR¹R², -C(O)OR¹, -SR¹, -SO₂R¹ y -SO₂NR¹R²; R¹ y R² se seleccionan independientemente, en cada instancia, del grupo que consiste en hidrógeno y alquilo C₁₋₆; Q se selecciona de -O-, S(O)ₙ- y -NR-; n es cero, 1 ó 2; R se selecciona de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₇, arilo o heteroarilo opcionalmente sustituido; -SO₂R³; -SO₂N(R³R⁴); -C(=O)R⁵; -C(=O)OR⁵; o -C(=O)N(R³R⁴); en donde dichos sustituyentes en el alquilo C₁₋₆, cicloalquilo C₃₋₇, arilo o heteroarilo se seleccionan del grupo que consiste en hidroxi, halógeno, ciano, nitro, amino, alquilamino C₁₋₄, dialquilamino C₁₋₄, acilamino C₁₋₄, alquilsulfonilo C₁₋₄, alquiltio C₁₋₄, alquilo C₁₋₄, cicloalquilo C₃₋₇, haloalquilo C₁₋₄, haloalcoxi C₁₋₄ y alcoxi C₁₋₄; R³ y R⁴ se seleccionan independientemente, en cada instancia, de hidrógeno, alquilo C₁₋₆, arilo y arilalquilo, en donde dicho arilo o el arilo del arilalquilo esté opcionalmente sustituido con hidroxi, halógeno, ciano, nitro, amino, alquilamino C₁₋₄, dialquilamino C₁₋₄, acilamino C₁₋₄, alquilsulfonilo C₁₋₄, alquiltio C₁₋₄, alquilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄ o alcoxi C₁₋₄; R⁵ se selecciona de hidrógeno, alquilo C₁₋₄ opcionalmente sustituido o arilo opcionalmente sustituido, en donde dichos sustituyentes opcionales se seleccionan del grupo que consiste en alquilo C₁₋₃, OR¹, NH₂, NHMe, N(Me)₂ y heterociclo; Y se selecciona de hidrógeno o hidroxilo; V se selecciona de fenilo, un anillo heteroaromático de seis miembros, furano y tiofeno; Z¹ y Z² se seleccionan independientemente, en cada instancia, del grupo que consiste en hidrógeno, halógeno, nitro, ciano, azida, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, haloalquiltio- C₁₋₆, -NR¹R², -NR¹C(O)R², -NR¹C(O)OR⁶, -OR¹, -C(O)R¹, -OC(O)R¹, -C(O)NR¹R², -C(O)OR¹, -SR¹, -SO₂R¹ y -SO₂NR¹R²; y R⁶ es hidrocarburo C₁₋₈.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216172P | 2015-09-09 | 2015-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105975A1 true AR105975A1 (es) | 2017-11-29 |
Family
ID=56936551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102755A AR105975A1 (es) | 2015-09-09 | 2016-09-09 | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10759790B2 (es) |
| EP (1) | EP3347355B1 (es) |
| JP (1) | JP6955485B2 (es) |
| CN (1) | CN108349961B (es) |
| AR (1) | AR105975A1 (es) |
| CA (1) | CA2997784A1 (es) |
| TW (1) | TW201808930A (es) |
| WO (1) | WO2017044569A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3116857B1 (en) | 2014-03-11 | 2019-02-06 | Icahn School of Medicine at Mount Sinai | Constrained tricyclic sulfonamides |
| JP2017512766A (ja) | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド |
| CA2994830A1 (en) * | 2015-08-06 | 2017-02-09 | Icahn School Of Medicine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
| WO2017044567A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| WO2021150700A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents |
| WO2021150697A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents |
| CN112778257A (zh) * | 2021-01-21 | 2021-05-11 | 香港科技大学 | 一种将糠醇氧化为二氢吡喃酮类衍生物的绿色方法 |
| US20240174611A1 (en) * | 2021-02-08 | 2024-05-30 | Rappta Therapeutics Oy | Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same |
| EP4543863A1 (en) * | 2022-06-23 | 2025-04-30 | University Of Ottawa | Ferroptosis inhibitors and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| EP0679641B1 (en) | 1993-07-26 | 2002-10-02 | Eisai Co., Ltd. | Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| US6583138B1 (en) | 1998-02-27 | 2003-06-24 | Eisai Co., Ltd. | Heterocyclic-ring condensed benzothiazine compound |
| WO2002024657A2 (en) | 2000-09-20 | 2002-03-28 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| JP4428053B2 (ja) | 2002-02-05 | 2010-03-10 | 味の素株式会社 | ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物 |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| WO2006066879A2 (en) | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| AP2007004234A0 (en) | 2005-04-22 | 2007-12-31 | Alantos Pharm Holding | Dipeptidyl peptidase-IV inhibitors |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| WO2008121859A1 (en) | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
| MX343687B (es) * | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. |
| CA2844985A1 (en) | 2011-08-16 | 2013-02-21 | Mt. Sinai School Of Medicine | Tricyclic compounds as anticancer agents |
| EP2887803A4 (en) | 2012-08-24 | 2016-08-03 | Univ Texas | PRO-NEUROGENIC COMPOUNDS |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| KR20150119390A (ko) | 2013-02-19 | 2015-10-23 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 항암제로서의 삼환식 헤테로사이클 |
| JP2017512766A (ja) * | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド |
| EP3116857B1 (en) | 2014-03-11 | 2019-02-06 | Icahn School of Medicine at Mount Sinai | Constrained tricyclic sulfonamides |
| CA2994830A1 (en) | 2015-08-06 | 2017-02-09 | Icahn School Of Medicine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
| WO2017044572A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Ring constrained diarylamino sulfonamides as anti-cancer agents |
| WO2017044567A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| WO2017044575A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| WO2017044571A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
-
2016
- 2016-09-08 CA CA2997784A patent/CA2997784A1/en not_active Abandoned
- 2016-09-08 WO PCT/US2016/050688 patent/WO2017044569A1/en not_active Ceased
- 2016-09-08 JP JP2018512955A patent/JP6955485B2/ja not_active Expired - Fee Related
- 2016-09-08 CN CN201680065550.9A patent/CN108349961B/zh not_active Expired - Fee Related
- 2016-09-08 US US15/758,045 patent/US10759790B2/en active Active
- 2016-09-08 EP EP16766454.9A patent/EP3347355B1/en not_active Not-in-force
- 2016-09-09 AR ARP160102755A patent/AR105975A1/es unknown
- 2016-09-09 TW TW105129416A patent/TW201808930A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3347355A1 (en) | 2018-07-18 |
| CA2997784A1 (en) | 2017-03-16 |
| TW201808930A (zh) | 2018-03-16 |
| HK1259348A1 (zh) | 2019-11-29 |
| WO2017044569A1 (en) | 2017-03-16 |
| JP6955485B2 (ja) | 2021-10-27 |
| US10759790B2 (en) | 2020-09-01 |
| US20180251456A1 (en) | 2018-09-06 |
| JP2018526419A (ja) | 2018-09-13 |
| CN108349961A (zh) | 2018-07-31 |
| CN108349961B (zh) | 2022-02-18 |
| EP3347355B1 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
| AR119046A1 (es) | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR118856A2 (es) | Compuestos terapéuticos | |
| AR123089A2 (es) | Compuesto de piridinona | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR110405A1 (es) | Compuestos | |
| AR095781A1 (es) | Inhibidores de proteínas de quinasa | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR091368A1 (es) | Compuestos y composiciones para modular la actividad de egfr | |
| AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR111850A1 (es) | Trifluorometiloxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |